Syros Pharmaceuticals, Inc. (SYRS) |
5.07 -0.07 (-1.36%) 04-24 16:00 |
Open: | 5.2 |
High: | 5.2 |
Low: | 5 |
Volume: | 89,493 |
Market Cap: | 134(M) |
PE Ratio: | -0.87 |
Exchange: | NASDAQ Global Select |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 6.49 |
Resistance 1: | 5.70 |
Pivot price: | 5.12 |
Support 1: | 4.41 |
Support 2: | 3.67 |
52w High: | 8.17 |
52w Low: | 2.09 |
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
EPS | -124250000.000 |
Book Value | 0.000 |
PEG Ratio | 0.00 |
Gross Profit | 0.000 |
Profit Margin (%) | 0.00 |
Operating Margin (%) | -6.00 |
Return on Assets (ttm) | 996.1 |
Return on Equity (ttm) | -38.3 |
Wed, 17 Apr 2024
Syros Pharmaceuticals (NASDAQ:SYRS) Shares Pass Below 50 Day Moving Average of $6.38 - MarketBeat
Wed, 10 Apr 2024
Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML - Yahoo Finance
Tue, 09 Apr 2024
Syros stock jumps on FDA fast track tag for leukemia drug - Seeking Alpha
Thu, 28 Mar 2024
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2023 Earnings Call Transcript - Yahoo Finance
Wed, 27 Mar 2024
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update - Business Wire
Wed, 27 Mar 2024
Syros Pharmaceuticals, Inc. (SYRS) Q4 2023 Earnings Call Transcript - Seeking Alpha
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |